7
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      The adaptive antioxidant response during fasting-induced muscle atrophy is oppositely regulated by ZEB1 and ZEB2

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Significance

          Reactive oxygen species (ROS) are normally produced by cells, but they must be constantly neutralized to prevent their supraphysiological levels from causing oxidative damage to cellular components. The study found that the transcription factors ZEB1 and ZEB2 activated and repressed, respectively, the adaptive antioxidant response to fasting in skeletal muscle. These findings suggest that ZEB factors could serve as potential therapeutic targets to modulate the antioxidant response in pathophysiological conditions.

          Abstract

          Reactive oxygen species (ROS) serve important homeostatic functions but must be constantly neutralized by an adaptive antioxidant response to prevent supraphysiological levels of ROS from causing oxidative damage to cellular components. Here, we report that the cellular plasticity transcription factors ZEB1 and ZEB2 modulate in opposing directions the adaptive antioxidant response to fasting in skeletal muscle. Using transgenic mice in which Zeb1 or Zeb2 were specifically deleted in skeletal myofibers, we show that in fasted mice, the deletion of Zeb1, but not Zeb2, increased ROS production and that the adaptive antioxidant response to fasting essentially requires ZEB1 and is inhibited by ZEB2. ZEB1 expression increased in fasted muscles and protected them from atrophy; conversely, ZEB2 expression in muscles decreased during fasting and exacerbated muscle atrophy. In fasted muscles, ZEB1 reduces mitochondrial damage and increases mitochondrial respiratory activity; meanwhile, ZEB2 did the opposite. Treatment of fasting mice with Zeb1-deficient myofibers with the antioxidant triterpenoid 1[2-cyano-3,12-dioxool-eana-1,9(11)-dien-28-oyl] trifluoro-ethylamide (CDDO-TFEA) completely reversed their altered phenotype to that observed in fasted control mice. These results set ZEB factors as potential therapeutic targets to modulate the adaptive antioxidant response in physiopathological conditions and diseases caused by redox imbalance.

          Related collections

          Most cited references36

          • Record: found
          • Abstract: found
          • Article: not found

          Reactive oxygen species (ROS) as pleiotropic physiological signalling agents

          'Reactive oxygen species' (ROS) is an umbrella term for an array of derivatives of molecular oxygen that occur as a normal attribute of aerobic life. Elevated formation of the different ROS leads to molecular damage, denoted as 'oxidative distress'. Here we focus on ROS at physiological levels and their central role in redox signalling via different post-translational modifications, denoted as 'oxidative eustress'. Two species, hydrogen peroxide (H2O2) and the superoxide anion radical (O2·-), are key redox signalling agents generated under the control of growth factors and cytokines by more than 40 enzymes, prominently including NADPH oxidases and the mitochondrial electron transport chain. At the low physiological levels in the nanomolar range, H2O2 is the major agent signalling through specific protein targets, which engage in metabolic regulation and stress responses to support cellular adaptation to a changing environment and stress. In addition, several other reactive species are involved in redox signalling, for instance nitric oxide, hydrogen sulfide and oxidized lipids. Recent methodological advances permit the assessment of molecular interactions of specific ROS molecules with specific targets in redox signalling pathways. Accordingly, major advances have occurred in understanding the role of these oxidants in physiology and disease, including the nervous, cardiovascular and immune systems, skeletal muscle and metabolic regulation as well as ageing and cancer. In the past, unspecific elimination of ROS by use of low molecular mass antioxidant compounds was not successful in counteracting disease initiation and progression in clinical trials. However, controlling specific ROS-mediated signalling pathways by selective targeting offers a perspective for a future of more refined redox medicine. This includes enzymatic defence systems such as those controlled by the stress-response transcription factors NRF2 and nuclear factor-κB, the role of trace elements such as selenium, the use of redox drugs and the modulation of environmental factors collectively known as the exposome (for example, nutrition, lifestyle and irradiation).
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Oxidative Stress in Cancer

            Contingent upon concentration, reactive oxygen species (ROS) influence cancer evolution in apparently contradictory ways, either initiating/stimulating tumorigenesis and supporting transformation/proliferation of cancer cells or causing cell death. To accommodate high ROS levels, tumor cells modify sulfur-based metabolism, NADPH generation, and the activity of antioxidant transcription factors. During initiation, genetic changes enable cell survival under high ROS levels by activating antioxidant transcription factors or increasing NADPH via the pentose phosphate pathway (PPP). During progression and metastasis, tumor cells adapt to oxidative stress by increasing NADPH in various ways, including activation of AMPK, the PPP, and reductive glutamine and folate metabolism.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              NRF2 and the Hallmarks of Cancer

              The transcription factor NRF2 is the master regulator of the cellular antioxidant response. Though recognized originally as a target of chemopreventive compounds that help prevent cancer and other maladies, accumulating evidence has established the NRF2 pathway as a driver of cancer progression, metastasis, and resistance to therapy. Recent studies have identified new functions for NRF2 in the regulation of metabolism and other essential cellular functions, establishing NRF2 as a truly pleiotropic transcription factor. In this review, we explore the roles of NRF2 in the hallmarks of cancer, indicating both tumor suppressive and tumor-promoting effects.
                Bookmark

                Author and article information

                Contributors
                Journal
                Proc Natl Acad Sci U S A
                Proc Natl Acad Sci U S A
                PNAS
                Proceedings of the National Academy of Sciences of the United States of America
                National Academy of Sciences
                0027-8424
                1091-6490
                10 November 2023
                14 November 2023
                10 May 2024
                : 120
                : 46
                : e2301120120
                Affiliations
                [1] aGroup of Gene Regulation in Stem Cells, Cell Plasticity, Differentiation, and Cancer, Institute of Biomedical Research August Pi Sunyer (IDIBAPS) , Barcelona 08036, Spain
                [2] bNational Center of Biotechnology (CSIC-CNB) and Center for Molecular Biology Severo Ochoa (CSIC-CBMSO), Transgenesis Facility, High Research Council (CSIC) and Autonomous University of Madrid, Cantoblanco , Madrid 28049, Spain
                [3] cGroup of Muscle Research and Mitochondrial Function, Institute of Biomedical Research August Pi Sunyer (IDIBAPS), University of Barcelona School of Medicine, Hospital Clínic of Barcelona, and Rare Diseases Networking Biomedical Research Center (CIBERer) , Barcelona 08036, Spain
                [4] dNational Center for Genomics Analysis (CNAG) , Barcelona 08028, Spain
                [5] eDepartment of Biomedicine, University of Barcelona School of Medicine, and Institute of Biomedical Research August Pi Sunyer (IDIBAPS) , Barcelona 08036, Spain
                [6] fMolecular Targets Program, Department of Medicine, James Graham Brown Cancer Center , Louisville, KY 40202
                [7] gCatalan Institution for Research and Advanced Studies (ICREA) , Barcelona 08010, Spain
                Author notes
                1To whom correspondence may be addressed. Email: idib412@ 123456recerca.clinic.cat .

                Edited by Douglas Wallace, University of Pennsylvania, Philadelphia, PA; received January 20, 2023; accepted September 26, 2023

                Author information
                https://orcid.org/0000-0002-5745-6119
                https://orcid.org/0000-0002-9313-1194
                https://orcid.org/0000-0002-2745-6505
                https://orcid.org/0000-0003-0558-1281
                https://orcid.org/0000-0002-7527-4829
                https://orcid.org/0000-0003-0361-2873
                https://orcid.org/0000-0003-4605-2634
                Article
                202301120
                10.1073/pnas.2301120120
                10655555
                37948583
                7983d43d-fdec-4438-a5af-9e4ce46e117f
                Copyright © 2023 the Author(s). Published by PNAS.

                This article is distributed under Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND).

                History
                : 20 January 2023
                : 26 September 2023
                Page count
                Pages: 11, Words: 7492
                Funding
                Funded by: Duchenne Parent Project, FundRef 501100007423;
                Award ID: DPPE/01_2018
                Award Recipient : Antonio Postigo
                Funded by: MEC | Agencia Estatal de Investigación (AEI), FundRef 501100011033;
                Award ID: SAF2017-84918-R and PID2020-116338RB-I00
                Award Recipient : Antonio Postigo
                Funded by: Government of Catalonia | Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR), FundRef 501100003030;
                Award ID: 2017-SGR-1174 and 2021-SGR 01328
                Award Recipient : Antonio Postigo
                Categories
                research-article, Research Article
                biochem, Biochemistry
                407
                Biological Sciences
                Biochemistry

                antioxidant response,nrf2,muscle atrophy,reactive oxygen species,zeb1 and zeb2

                Comments

                Comment on this article